ERBB2 and breast carcinoma: An international multicenter cohort study of 28,280 non-metastatic breast cancer patients described that better recurrence free survival and OS of HER2-low did not correlate with HER2 IHC score and mainly resulted from the HER2 IHC1+ subgroup [12].